Docoh
Loading...

MTCR Metacrine

APP
Utility
Crystalline Forms of a Farnesoid X Receptor Agonist
11 Nov 21
Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
Nicholas D. SMITH, Robert MANSFIELD
Filed: 17 Sep 19
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
30 Sep 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 19 Jan 21
GRANT
Utility
Farnesoid X receptor agonists and uses thereof
10 Aug 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Karensa L. Douglas, Andiliy G. Lai
Filed: 17 Sep 19
GRANT
Utility
Farnesoid X receptor agonists and uses thereof
30 Mar 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Filed: 14 Mar 18
GRANT
Utility
Farnesoid X receptor agonists and uses thereof
23 Feb 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Stephen P. Govek, Johnny Y. Nagasawa
Filed: 28 May 20
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
4 Feb 21
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 12 May 20
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
16 Sep 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Stephen P. GOVEK, Johnny Y. NAGASAWA
Filed: 27 May 20
GRANT
Utility
Farnesoid X receptor agonists and uses thereof
6 Jul 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Filed: 15 Sep 16
APP
Utility
Ssao Inhibitors and Uses Thereof
10 Jun 20
Described herein are compounds that are semicarbazide-sensitive amine oxidase (SSAO) inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating or preventing a liver disease or condition.
Nicholas D. Smith, Andrew R. Hudson, Mi Chen, Johnny Y. Nagasawa, Iriny Botrous
Filed: 13 Feb 20
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Andiliy G. LAI
Filed: 13 Mar 18
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 13 Mar 18
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA
Filed: 13 Mar 18
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
29 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Johnny Y. NAGASAWA, Karensa L. Douglas
Filed: 13 Mar 18
GRANT
Utility
Farnesoid X receptor agonists and uses thereof
20 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
Filed: 15 Sep 16
APP
Utility
Farnesoid X Receptor Agonists and Uses Thereof
1 Apr 20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
Nicholas D. SMITH, Steven P. GOVEK, Karensa L. DOUGLAS, Andiliy G. LAI
Filed: 16 Sep 19
  • 1
Patents are sorted by USPTO publication date, most recent first